INGELHEIM, Germany - Saturday, November 2nd 2013 [ME NewsWire]
Pivotal Phase III STARTVerso™ data show efficacy of faldaprevir* in difficult-to-cure patient populations such as those with HIV co-infection and advanced liver disease
84% of patients benefited from a shorter time on treatment and the majority went on to achieve viral cure, with no compromise on safety and tolerability (STARTVerso™1&2)1
Second-generation protease inhibitor faldaprevir* is being investigated in combinations both with and without interferon
(BUSINESS WIRE)-- For media outside of the U.S.A., UK and Canada only
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso™, which evaluates faldaprevir* in combination with pegylated interferon and ribavirin (PegIFN/RBV). Patients with genotype-1 (GT-1) hepatitis C (HCV) who have not received previous treatment (treatment-naïve: STARTVerso™1&2),1 treatment-experienced patients (STARTVerso™3),2 and HIV co-infected patients (STARTVerso™4)3 participated in this study programme. The results from these and additional studies will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting®, taking place 1-5 November in Washington, D.C.
In STARTVerso™1&2, 84% of treatment-naïve patients receiving faldaprevir* were able to shorten the total time on treatment from 48 to 24 weeks; 83% of these patients achieved viral cure (SVR12).1 Overall, 73% and 72% of patients achieved SVR12 with faldaprevir* 120mg and 240mg regimens, respectively. Interim results from STARTVerso™4 showed that 74% of patients with HCV/HIV co-infection treated with faldaprevir* had undetectable HCV 4 weeks after the conclusion of treatment (SVR4), a response rate similar to that seen with HCV mono-infection.3 Additionally, treatment of difficult-to-cure patients who have relapsed on previous HCV treatment (STARTVerso™3) demonstrated viral cure rates of 70% with faldaprevir*.2 In the same study, patients who partially responded and those who showed no response to previous treatment achieved viral cure rates of up to 58% and 33%, respectively.3 For the full STARTVerso™ results, see notes to editors.
“These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment for genotype-1 infected HCV patients,” said Ira Jacobson, M.D., Chief of the Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York. “The broad populations studied in STARTVerso™ and the fact that very few patients discontinued treatment due to adverse events provides physicians with confidence in faldaprevir* as an important potential addition to the available agents for the treatment of hepatitis C.”
More than 2,200 patients have been studied in the STARTVerso™ trial programme, including patients with difficult-to-cure types of HCV:
Over 300 patients in the programme have HCV/HIV co-infection;3 these patients have higher levels of HCV in their blood and can be more difficult to cure4
677 patients were treatment-experienced, meaning they had attempted previous HCV treatment but did not achieve viral cure2
40% of patients in STARTVerso™3 had advanced liver disease (≥F3 fibrosis)2
59% of patients in STARTVerso™1&2 had a non-CC IL28B genotype;1 in previous studies, these patients were less likely to achieve viral cure5
“The STARTVerso™ trial results are particularly promising given the inclusion of a broad range of patients and the similar success rates seen in both HCV mono and HCV/HIV co-infected patients. These data will form the basis of regulatory submissions and we look forward to the outcome,” said Professor Klaus Dugi, Senior Vice President Medicine at Boehringer Ingelheim. “Faldaprevir* may offer a simple and convenient option for patients, due to once-daily dosing and no food restrictions. Faldaprevir* is the foundation of our HCV pipeline and we look forward to presenting pivotal Phase III HCVerso® data for the treatment of HCV as part of an interferon-free regimen in 2014.”
Faldaprevir* as part of this interferon-based regimen is likely to offer advantages over first generation protease inhibitors with fewer skin reactions, gastrointestinal events and no additional anaemia. In the STARTVerso™ clinical trial programme, adverse events (AEs) were generally mild and well manageable. Most common AEs included jaundice due to transient bilirubin elevation (unconjugated hyperbilirubinemia), nausea, fatigue, diarrhoea, headache, anaemia and rash. 95% of patients completed faldaprevir* treatment.1,2,3 For full STARTVerso™ results, see notes to editors.
ADDITIONAL BOEHRINGER INGELHEIM DATA AT THE MEETING
Faldaprevir* in further clinical settings
Further studies adding to the robust portfolio of evidence for faldaprevir* will be presented at the meeting. These include studies exploring drug-drug interactions in patients who are taking oral birth control pills and common medication to treat drug dependence and studies evaluating faldaprevir* in patients who have renal impairment.
Faldaprevir* as part of an interferon-free regimen
Additional news from Boehringer Ingelheim was released today featuring data from the collaborative trial with Presidio Pharmaceuticals. The ongoing Phase II trial investigating the regimen of faldaprevir*, deleobuvir* and PPI-668 (with and without ribavirin) in genotype-1a infected patients was accepted as late breaker and will be presented on Monday.
* Faldaprevir and deleobuvir are investigational compounds and not yet approved. Their safety and efficacy have not yet been fully established.
^SVR12 = sustained viral response 12 weeks after treatment completion, also described as “viral cure”
# # #
NOTES TO EDITORS
Phase III STARTVerso™ results
STARTVerso™1&2 Treatment-naïve patients were randomised 1:2:2 to receive 48 weeks of PegIFN/RBV plus: placebo (Arm 1); faldaprevir* 120mg once-daily for 12 or 24 weeks (Arm 2); or faldaprevir* 240mg once-daily for 12 weeks (Arm 3). SVR12 rates were:1
Arm 1: 50% (131/264)
Arm 2: 73% (382/521)
Arm 3: 72% (378/524)
Patients in arms 2 and 3 stopped all treatment at week 24 if HCV RNA <25IU/mL was detected or undetected at week 4 and undetected at week 8 of treatment. Results were:1
Arm 2: 84% (436/521) of which 83% (362/436) achieved SVR12
Arm 3: 84% (441/524) of which 83% (368/441) achieved SVR12
In the study, the most common AEs were gastrointestinal events and anaemia, occurring in 11%/18% and 14%/13% of patients treated with 120mg/240mg faldaprevir* regimens respectively. Hyperbilirubinemia occurred in 12% and 46% of patients, respectively.1
STARTVerso™3 The trial included 3 cohorts of treatment-experienced patients who had: prior relapse (cohort 1), prior partial response (cohort 2) and prior null response (cohort 3).2
Cohort 1 Patients were randomised 1:2:2 to receive 48 weeks of PegIFN/RBV plus: placebo (placebo); faldaprevir* 240mg once-daily for 12 weeks (FDV12W); or faldaprevir* 240mg once-daily for 24 weeks (FDV24W). SVR12 rates were:2
Placebo: 14% (7/49)
FDV12W: 70% (69/99)
FDV24W: 70% (71/102)
87% of patients stopped all treatment at week 24 of whom 75% achieved SVR12
Cohort 2 Patients were randomised 1:2:2 to receive 48 weeks of PegIFN/RBV plus: placebo (placebo); faldaprevir* 240mg once-daily for 12 weeks (FDV12W); or faldaprevir* 240mg once-daily for 24 weeks (FDV24W). SVR12 rates were:2
Placebo: 3% (1/29)
FDV12W: 58% (33/57)
FDV24W: 47% (26/55)
Cohort 3 Patients were randomised 1:1 to receive faldaprevir* 240mg once-daily for 12 weeks (FDV12W) or faldaprevir* 240mg once-daily for 24 weeks (FDV24W) with PegIFN/RBV for 48 weeks. SVR12 rates were:2
FDV12W: 33% (48/145)
FDV24W: 33% (46/141)
AEs of at least moderate intensity included gastrointestinal side effects, which occurred in 20% and 17% of patients in the 12- and 24-week faldaprevir* arms respectively. Also, anemia occurred in 10% of patients in both faldaprevir* arms.2
STARTVerso™4 The ongoing trial includes patients co-infected with HCV and HIV who are HCV treatment-naïve or have relapsed after previous HCV therapy. Patients received 48 weeks of PegIFN/RBV plus either: faldaprevir* 120mg once-daily for 24 weeks (Arm A); or faldaprevir* 240mg once-daily for 12 or 24 weeks (dependent on randomisation at week 12) (Arm B). SVR4 rates were:3
Arm A: 72% (89/123)
Arm B, faldaprevir* 12 weeks: 79% (66/84)
Arm B, faldaprevir* 24 weeks: 84% (72/86)
Arm B, total: 76% (140/185a)
Total: 74% (229/308)
aincludes additional patients from 240mg treatment group who discontinued prior to week 12
Patients in whom HCV RNA <25IU/mL was detected or undetected at week 4 and undetected at week 8, were randomised 1:1 to stop treatment at week 24 or continue PegIFN/RBV to 48 weeks. Results were:3
Arm A: 77% (95/123) of which 89% (85/95) achieved SVR4
Arm B, total: 81% (150/185) of which 87% (131/150) achieved SVR4
Total: 80% (245/308) of which 88% (216/245) achieved SVR4
The most common AEs in the study were nausea, fatigue and diarrhoea , occurring in 28% and 44%; 32% and 35%; and 25% and 28% with the 120mg and 240mg faldaprevir* regimens respectively.3
The Boehringer Ingelheim NewsHome: An innovative resource for journalists
The Boehringer Ingelheim hepatitis C www.newshome.com is the one-stop-shop for clear, concise and easy to understand information about hepatitis C for media.
For the full ‘Notes to Editors’ and ‘References’ please visit:
https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/02_novermber_2013_hepatitisc.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Reinhard Malin
Tel: +49 (6132) 77-90815
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/9057/en
Monday, November 4, 2013
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data
INGELHEIM, Germany - Saturday, November 2nd 2013 [ME NewsWire]
High rate of virologic response in Phase II hepatitis C trial of a 12 week all-oral combination of Boehringer Ingelheim’s faldaprevir* and deleobuvir* and Presidio’s PPI-668* with and without ribavirin1
All patients (17/17) who have completed treatment achieved undetectable levels of hepatitis C virus at the end of treatment1
13 of these patients have reached their 4-week post-treatment follow-up and all have undetectable hepatitis C virus (SVR4)1
(BUSINESS WIRE)-- For media outside of the U.S.A., UK and Canada only
Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir*, deleobuvir*, PPI-668* and ribavirin.1 These data from Boehringer Ingelheim’s ongoing Phase II collaborative trial with Presidio Pharmaceuticals will be presented on Monday during the ‘Late-Breaking Posters’ session at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, D.C. Additional data from the trial show 100% of patients (12/12) treated with a ribavirin-free regimen had hepatitis C virus (HCV) levels below the lower level of quantification at 4 weeks.1 Safety and tolerability appears to be better in this ribavirin-free treatment arm compared to those with ribavirin.1
“These interim results add to the growing body of evidence for faldaprevir* as an effective treatment for a broad range of genotype-1 infected hepatitis C patients, including the more difficult-to-cure. The trial is still in the early stages but the initial results look promising,” said Professor Klaus Dugi, Senior Vice President of Medicine at Boehringer Ingelheim. “These data further demonstrate the future potential of faldaprevir* as the foundation of interferon-free treatment regimens. Our pivotal HCVerso® studies which investigate the interferon-free regimen of faldaprevir*, deleobuvir* and ribavirin are currently in Phase III development. We look forward to the final results from both trials in Q2 next year.”
The ongoing Phase II trial features the 12-week regimen both with and without ribavirin in 36 genotype-1a infected patients, one of the more difficult-to-cure types of hepatitis C virus. In addition, more than half the patients in the study (20/36) had pre-existing HCV mutations. This includes the Q80K variant which is common in genotype-1a infected patients2 and has been associated with reduced responses to some HCV protease inhibitors3. Notably, all 12 patients in the study with pre-existing Q80K mutations are responding well to treatment with the faldaprevir*-based interferon-free regimen.1
To date, all patients in the study have received at least 4 weeks of treatment and 97% (35/36) achieved HCV levels below the lower limit of quantification at week 4. One patient had an initial virologic response but then exhibited viral breakthrough and was discontinued after 5 weeks of treatment. Overall, adverse events in the study have been mild to moderate, with the incidence and severity of skin rashes and gastrointestinal side effects similar to those observed in previous trials studying faldaprevir* and deleobuvir*. For further results see notes to editors.
Overview of Boehringer Ingelheim’s HCV trial programme
Boehringer Ingelheim’s hepatitis C clinical trial programme includes a broad range of genotype-1 infected patients. The programme features three treatment regimens, with faldaprevir* as the foundation:
Study
Regimen
Population
Status
STARTVerso™
Faldaprevir* pegylated interferon, ribavirin
GT-1 , TN, TE, HCV/HIV co-infection, advanced liver disease
Regulatory submissions pending
For results see the STARTVerso press release here
HCVerso®
Faldaprevir*, deleobuvir*, ribavirin
GT-1b, TN, TE, advanced liver disease
Phase III results expected Q2 2014
Presidio collaboration
Faldaprevir*, deleobuvir*, PPI-668* +/- ribavirin
GT-1a, TN, non-cc IL28B
Phase II final results expected Q2 2014
An individualised approach to hepatitis C
The breadth of patients studied in Boehringer Ingelheim’s hepatitis C trial programme reflects a population that physicians see in the clinic, including those with difficult types of hepatitis C virus to cure.
“The huge diversity between hepatitis C patients, due to differing personal factors and variations in the virus, highlight the importance of an individualised approach to treatment,” said Graham Foster, Professor of Hepatology, Queen Mary’s, London. “The difference between HCV genotypes is substantial. For example, genotype-1a and 1b share only around 70% of the same genetic material which is more distant than the genetic similarity between humans and some other animals and patients have differing degrees of liver damage that may require changes to the therapeutic approach. Given the diversity of the disease and the virus it is likely that each patient will need to be assessed on an individual basis and the best treatment assigned accordingly.”
For more information on the importance of an individualised approach to hepatitis C, view the video here
*Faldaprevir, deleobuvir and PPI668 are investigational compounds and not yet approved. Their safety and efficacy have not yet been fully established.
# # #
NOTES TO EDITORS
Phase IIa Presidio collaboration trial results
The trial includes 36 treatment-naïve patients with genotype-1a HCV treated for 12 weeks with an all-oral regimen, with 24 weeks of post-treatment follow-up. The primary endpoint is viral cure 12 weeks after treatment completion (SVR12). There are three cohorts in this study:1
Cohort 1: faldaprevir* 120 mg once-daily (QD), PPI-668 200mg QD and deleobuvir* 600mg twice-daily (BID) with ribavirin (n=12)
Cohort 2: faldaprevir* 120 mg QD, PPI-668 200mg QD and deleobuvir* 400mg BID with ribavirin (n=12)
Cohort 3: faldaprevir* 120mg QD, PPI-668 200mg QD and deleobuvir* 600 mg BID, without ribavirin (n=12)
Thirty-six patients in this study have reached week 4 of treatment, 17 patients have reached the end of treatment (12 weeks) and 13 patients have reached their 4 week post-treatment follow-up. Interim results show:1
97% of patients (35/36) achieved HCV levels below the lower limit of quantification at week 4
100% of patients (17/17) that completed the full course of treatment had undetectable hepatitis C virus at the conclusion of treatment
100% of patients (13/13) that completed the full course of treatment achieved SVR4
To date there has been just one treatment failure due to viral breakthrough. One patient had an initial virologic response but then exhibited viral breakthrough and was discontinued after 5 weeks of treatment. Only one AE was rated as ‘severe’ and attributable to study drugs; one patient reported severe fatigue in week 11 and the event was resolved with no change in treatment.1
NewsHome
The Boehringer Ingelheim NewsHome: An innovative resource for journalists
The Boehringer Ingelheim hepatitis C www.newshome.com is the one-stop-shop for clear, concise and easy to understand information about hepatitis C for the media.
About STARTVerso™ and HCVerso®
For information on the interferon-free Phase III HCVerso® trials please refer to the Clinical Trials backgrounder, available on NewsHome.
For the full ‘Notes to Editors’ and ‘References’ please visit:
https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/02_novermber_2013_hepatitisc1.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Reinhard Malin
Tel: +49 (6132) 77-90815
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/9058/en
High rate of virologic response in Phase II hepatitis C trial of a 12 week all-oral combination of Boehringer Ingelheim’s faldaprevir* and deleobuvir* and Presidio’s PPI-668* with and without ribavirin1
All patients (17/17) who have completed treatment achieved undetectable levels of hepatitis C virus at the end of treatment1
13 of these patients have reached their 4-week post-treatment follow-up and all have undetectable hepatitis C virus (SVR4)1
(BUSINESS WIRE)-- For media outside of the U.S.A., UK and Canada only
Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir*, deleobuvir*, PPI-668* and ribavirin.1 These data from Boehringer Ingelheim’s ongoing Phase II collaborative trial with Presidio Pharmaceuticals will be presented on Monday during the ‘Late-Breaking Posters’ session at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, D.C. Additional data from the trial show 100% of patients (12/12) treated with a ribavirin-free regimen had hepatitis C virus (HCV) levels below the lower level of quantification at 4 weeks.1 Safety and tolerability appears to be better in this ribavirin-free treatment arm compared to those with ribavirin.1
“These interim results add to the growing body of evidence for faldaprevir* as an effective treatment for a broad range of genotype-1 infected hepatitis C patients, including the more difficult-to-cure. The trial is still in the early stages but the initial results look promising,” said Professor Klaus Dugi, Senior Vice President of Medicine at Boehringer Ingelheim. “These data further demonstrate the future potential of faldaprevir* as the foundation of interferon-free treatment regimens. Our pivotal HCVerso® studies which investigate the interferon-free regimen of faldaprevir*, deleobuvir* and ribavirin are currently in Phase III development. We look forward to the final results from both trials in Q2 next year.”
The ongoing Phase II trial features the 12-week regimen both with and without ribavirin in 36 genotype-1a infected patients, one of the more difficult-to-cure types of hepatitis C virus. In addition, more than half the patients in the study (20/36) had pre-existing HCV mutations. This includes the Q80K variant which is common in genotype-1a infected patients2 and has been associated with reduced responses to some HCV protease inhibitors3. Notably, all 12 patients in the study with pre-existing Q80K mutations are responding well to treatment with the faldaprevir*-based interferon-free regimen.1
To date, all patients in the study have received at least 4 weeks of treatment and 97% (35/36) achieved HCV levels below the lower limit of quantification at week 4. One patient had an initial virologic response but then exhibited viral breakthrough and was discontinued after 5 weeks of treatment. Overall, adverse events in the study have been mild to moderate, with the incidence and severity of skin rashes and gastrointestinal side effects similar to those observed in previous trials studying faldaprevir* and deleobuvir*. For further results see notes to editors.
Overview of Boehringer Ingelheim’s HCV trial programme
Boehringer Ingelheim’s hepatitis C clinical trial programme includes a broad range of genotype-1 infected patients. The programme features three treatment regimens, with faldaprevir* as the foundation:
Study
Regimen
Population
Status
STARTVerso™
Faldaprevir* pegylated interferon, ribavirin
GT-1 , TN, TE, HCV/HIV co-infection, advanced liver disease
Regulatory submissions pending
For results see the STARTVerso press release here
HCVerso®
Faldaprevir*, deleobuvir*, ribavirin
GT-1b, TN, TE, advanced liver disease
Phase III results expected Q2 2014
Presidio collaboration
Faldaprevir*, deleobuvir*, PPI-668* +/- ribavirin
GT-1a, TN, non-cc IL28B
Phase II final results expected Q2 2014
An individualised approach to hepatitis C
The breadth of patients studied in Boehringer Ingelheim’s hepatitis C trial programme reflects a population that physicians see in the clinic, including those with difficult types of hepatitis C virus to cure.
“The huge diversity between hepatitis C patients, due to differing personal factors and variations in the virus, highlight the importance of an individualised approach to treatment,” said Graham Foster, Professor of Hepatology, Queen Mary’s, London. “The difference between HCV genotypes is substantial. For example, genotype-1a and 1b share only around 70% of the same genetic material which is more distant than the genetic similarity between humans and some other animals and patients have differing degrees of liver damage that may require changes to the therapeutic approach. Given the diversity of the disease and the virus it is likely that each patient will need to be assessed on an individual basis and the best treatment assigned accordingly.”
For more information on the importance of an individualised approach to hepatitis C, view the video here
*Faldaprevir, deleobuvir and PPI668 are investigational compounds and not yet approved. Their safety and efficacy have not yet been fully established.
# # #
NOTES TO EDITORS
Phase IIa Presidio collaboration trial results
The trial includes 36 treatment-naïve patients with genotype-1a HCV treated for 12 weeks with an all-oral regimen, with 24 weeks of post-treatment follow-up. The primary endpoint is viral cure 12 weeks after treatment completion (SVR12). There are three cohorts in this study:1
Cohort 1: faldaprevir* 120 mg once-daily (QD), PPI-668 200mg QD and deleobuvir* 600mg twice-daily (BID) with ribavirin (n=12)
Cohort 2: faldaprevir* 120 mg QD, PPI-668 200mg QD and deleobuvir* 400mg BID with ribavirin (n=12)
Cohort 3: faldaprevir* 120mg QD, PPI-668 200mg QD and deleobuvir* 600 mg BID, without ribavirin (n=12)
Thirty-six patients in this study have reached week 4 of treatment, 17 patients have reached the end of treatment (12 weeks) and 13 patients have reached their 4 week post-treatment follow-up. Interim results show:1
97% of patients (35/36) achieved HCV levels below the lower limit of quantification at week 4
100% of patients (17/17) that completed the full course of treatment had undetectable hepatitis C virus at the conclusion of treatment
100% of patients (13/13) that completed the full course of treatment achieved SVR4
To date there has been just one treatment failure due to viral breakthrough. One patient had an initial virologic response but then exhibited viral breakthrough and was discontinued after 5 weeks of treatment. Only one AE was rated as ‘severe’ and attributable to study drugs; one patient reported severe fatigue in week 11 and the event was resolved with no change in treatment.1
NewsHome
The Boehringer Ingelheim NewsHome: An innovative resource for journalists
The Boehringer Ingelheim hepatitis C www.newshome.com is the one-stop-shop for clear, concise and easy to understand information about hepatitis C for the media.
About STARTVerso™ and HCVerso®
For information on the interferon-free Phase III HCVerso® trials please refer to the Clinical Trials backgrounder, available on NewsHome.
For the full ‘Notes to Editors’ and ‘References’ please visit:
https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/02_novermber_2013_hepatitisc1.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Reinhard Malin
Tel: +49 (6132) 77-90815
Fax: +49 (6132) 77-6601
Email: press@boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/9058/en
Sunday, November 3, 2013
Chicago-Based Performance Trust Investment Advisors, LLC (PTIA) Changes Name To Performance Trust Asset Management, LLC (PTAM)
CHICAGO - Saturday, November 2nd 2013 [ME NewsWire]
(BUSINESS WIRE)-- Chicago-based Performance Trust Investment Advisors, LLC (PTIA) is changing its name to Performance Trust Asset Management, LLC (PTAM).
Firm president Doug Rothschild explains, “The new name better reflects our primary focus on being an asset manager for institutional investors.” PTAM launched its first hedge fund in 2008, capturing opportunity for investors in the then-severely distressed residential mortgage-backed securities market. Since then, the firm has grown rapidly in terms of both assets and products.
Today, PTAM is an institutional-class platform employing a team of industry veterans with a broad scope of fixed income and credit expertise, including the recent hiring of Ethan Youderian, well known in industry circles for his time as Senior Portfolio Manager and Managing Director at Citadel Investment Group. Youderian is now leading the development of PTAM’s newest product, a fixed income-focused hedge fund vehicle expected to launch in the first quarter of 2014.
Performance Trust Asset Management, LLC is a Chicago-based alternative investment firm specializing in the credit and fixed income markets. PTAM seeks attractive investment returns by operating in complex markets where inefficiencies create unique drivers of return. The firm currently manages approximately $1 billion (as of September 30, 2013) of institutional and individual assets across multiple pooled investment vehicles, mutual funds, and separately managed accounts.
The ticker symbols for PTAM’s two mutual fund products will remain unchanged.
For more information, go to www.PTAM.com.
Contacts
Performance Trust Asset Management, LLC
Rick Sterioti, 312-521-1406
(BUSINESS WIRE)-- Chicago-based Performance Trust Investment Advisors, LLC (PTIA) is changing its name to Performance Trust Asset Management, LLC (PTAM).
Firm president Doug Rothschild explains, “The new name better reflects our primary focus on being an asset manager for institutional investors.” PTAM launched its first hedge fund in 2008, capturing opportunity for investors in the then-severely distressed residential mortgage-backed securities market. Since then, the firm has grown rapidly in terms of both assets and products.
Today, PTAM is an institutional-class platform employing a team of industry veterans with a broad scope of fixed income and credit expertise, including the recent hiring of Ethan Youderian, well known in industry circles for his time as Senior Portfolio Manager and Managing Director at Citadel Investment Group. Youderian is now leading the development of PTAM’s newest product, a fixed income-focused hedge fund vehicle expected to launch in the first quarter of 2014.
Performance Trust Asset Management, LLC is a Chicago-based alternative investment firm specializing in the credit and fixed income markets. PTAM seeks attractive investment returns by operating in complex markets where inefficiencies create unique drivers of return. The firm currently manages approximately $1 billion (as of September 30, 2013) of institutional and individual assets across multiple pooled investment vehicles, mutual funds, and separately managed accounts.
The ticker symbols for PTAM’s two mutual fund products will remain unchanged.
For more information, go to www.PTAM.com.
Contacts
Performance Trust Asset Management, LLC
Rick Sterioti, 312-521-1406
PerkinElmer’s DairyGuard™ is the First Analyzer to Add Screening for Unknown Adulterants in Milk Powder
Suppliers and manufacturers can screen faster for more known and unknown risks
WALTHAM, Mass - Friday, November 1st 2013 [ME NewsWire]
(BUSINESS WIRE) PerkinElmer, Inc., a global leader in improving the health and safety of people and the environment, today introduced the DairyGuard™ milk powder analyzer, a near infrared (NIR) spectrometer specifically developed for food suppliers and manufacturers. DairyGuard is the only system available that tests for unknown adulterants as well as known compounds, such as protein, moisture and fat content. Combined with faster preparation and sampling times that yield real-time results, DairyGuard provides heightened protection from supply chain risks to the safety and quality of milk powder.
With growing supply chain complexities and liability for potential recalls, food manufacturers are in need of a turnkey solution to accurately and cost-effectively screen both known and unknown contaminants in milk powder supplies. The DairyGuard analyzer’s preconfigured mathematical models of specific analytical profiles for milk powder – similar to a fingerprint – eliminates the need for upfront instrument configuration. In less than a minute, DairyGuard accurately tells whether a batch is safe to continue into manufacturing or if further analysis is required.
“Milk powder has been identified by many agencies as an ingredient with high risk for adulteration, creating a greater need for all food manufacturers to employ a reliable screening method,” said Sharon Palmer, food director, PerkinElmer. “To avoid food safety issues, such as the melamine incident in 2008, food manufacturers have to screen for not only known contaminants like pesticides and drug residues, but also unknown contaminants that might be unsafe substitutions. DairyGuard will give food suppliers greater confidence in their ingredients and help to ensure a safe end product for the consumer.”
“Infrared technologies have become a critical tool in our work to detect clandestine and economic adulteration in dietary supplements,” said James Neal-Kababick, director, Flora Research Labs. “The speed of analysis is unmatched by any other method we use and the ability to do non-destructive testing is essential in our phytoforensic work, especially when very limited sample is available. I consider having an infrared system in the laboratory as fundamental as having a balance. I could not imagine being without one. PerkinElmer technologies, like the infrared system in DairyGuard, have helped us solve some of the most complex cases of food and supplement contamination we have encountered.”
According to a 2010 A.T. Kearney study conducted for the Grocery Manufacturers Association (GMA), the cost of one adulteration incident averages between 2 and 15 percent of a company’s yearly revenues. Investments in the people and technology to ensure streamlined screening protocols are enabling processors and manufacturers to avoid the threats that contamination poses to customers and company reputations.
For more information on dairy analysis and other food safety solutions visit www.perkinelmer.com/food or stop by our booth at Dairy International, Chicago, Booth #341.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. Join the conversation and follow us on twitter at www.twitter.com/perkinelmernews.
Contacts
Edelman (On behalf of PerkinElmer, Inc.)
Brittney Haynes, 404-460-9664
Brittney.haynes@edelman.com
WALTHAM, Mass - Friday, November 1st 2013 [ME NewsWire]
(BUSINESS WIRE) PerkinElmer, Inc., a global leader in improving the health and safety of people and the environment, today introduced the DairyGuard™ milk powder analyzer, a near infrared (NIR) spectrometer specifically developed for food suppliers and manufacturers. DairyGuard is the only system available that tests for unknown adulterants as well as known compounds, such as protein, moisture and fat content. Combined with faster preparation and sampling times that yield real-time results, DairyGuard provides heightened protection from supply chain risks to the safety and quality of milk powder.
With growing supply chain complexities and liability for potential recalls, food manufacturers are in need of a turnkey solution to accurately and cost-effectively screen both known and unknown contaminants in milk powder supplies. The DairyGuard analyzer’s preconfigured mathematical models of specific analytical profiles for milk powder – similar to a fingerprint – eliminates the need for upfront instrument configuration. In less than a minute, DairyGuard accurately tells whether a batch is safe to continue into manufacturing or if further analysis is required.
“Milk powder has been identified by many agencies as an ingredient with high risk for adulteration, creating a greater need for all food manufacturers to employ a reliable screening method,” said Sharon Palmer, food director, PerkinElmer. “To avoid food safety issues, such as the melamine incident in 2008, food manufacturers have to screen for not only known contaminants like pesticides and drug residues, but also unknown contaminants that might be unsafe substitutions. DairyGuard will give food suppliers greater confidence in their ingredients and help to ensure a safe end product for the consumer.”
“Infrared technologies have become a critical tool in our work to detect clandestine and economic adulteration in dietary supplements,” said James Neal-Kababick, director, Flora Research Labs. “The speed of analysis is unmatched by any other method we use and the ability to do non-destructive testing is essential in our phytoforensic work, especially when very limited sample is available. I consider having an infrared system in the laboratory as fundamental as having a balance. I could not imagine being without one. PerkinElmer technologies, like the infrared system in DairyGuard, have helped us solve some of the most complex cases of food and supplement contamination we have encountered.”
According to a 2010 A.T. Kearney study conducted for the Grocery Manufacturers Association (GMA), the cost of one adulteration incident averages between 2 and 15 percent of a company’s yearly revenues. Investments in the people and technology to ensure streamlined screening protocols are enabling processors and manufacturers to avoid the threats that contamination poses to customers and company reputations.
For more information on dairy analysis and other food safety solutions visit www.perkinelmer.com/food or stop by our booth at Dairy International, Chicago, Booth #341.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. Join the conversation and follow us on twitter at www.twitter.com/perkinelmernews.
Contacts
Edelman (On behalf of PerkinElmer, Inc.)
Brittney Haynes, 404-460-9664
Brittney.haynes@edelman.com
electroCore's clinical trial program into non invasive vagus nerve stimulation therapy gathers momentum
BASKING RIDGE, New Jersey - Friday, November 1st 2013 [ME NewsWire]
(BUSINESS WIRE)-- Following the announcement last month that it had fully enrolled its pilot FDA chronic migraine study electroCore has announced that its European randomized controlled trial, GC - 002, for the prevention and acute treatment of chronic cluster headache has been found by the external statistical team to require no changes based on the planned interim sizing analysis.
This study, which is a multicentre trial with sites in Germany -5, UK -3, Belgium -1, Italy -1, has as its primary outcome the reduction in the number of cluster headache attacks per week. The trial is a randomized controlled study involving parallel groups. One arm receiving the standard of care while the other arm is receiving the standard of care plus treatment with gammaCore - electroCore's non invasive vagus nerve stimulation (nVNS) therapy. The trial, which is due to finish at the end of the second quarter next year, has already enrolled 58 patients with a target total of 90 patients.
electroCore's extensive clinical trials program is continuing to explore the potential of its revolutionary non invasive vagus nerve stimulation therapy across a number of conditions. Surgically invasive vagus nerve stimulation therapy has proven to be very effective in epilepsy and depression but because of its very high cost is not used except as a last resort. Its high cost has also deterred research into the many conditions where it is reported to have been effective.
Several other key electroCore headache trials are also underway.
A European acute treatment of cluster headache trial has just started recruitment.
This randomized controlled study has two parallel groups one using gammaCore, the other a sham device. The trial is being run across eight sites - UK - 4, Germany 2, Denmark -1 and Netherlands 1. The results are expected in the third quarter of next year.
A pivotal FDA trial into the acute relief of cluster headaches is being carried out across nineteen sites in the US with 78 patients already enrolled. The final number of patients required, between 150 and 300, will be determined by an interim analysis by an outside statistical team based on the first 75 completed patients by the end of the year. This trial is measuring the level of pain on a five point scale 15 minutes after patients have self treated an acute cluster headache attack with the gammaCore device. The results are expected at the end of next year.
An epilepsy trial using electroCore’s nVNS therapy, the first clinical study of nVNS in this indication, is now being run at two sites in Australia. The randomized controlled, parallel-group, crossover trial using a sham device will measure the reduction of seizures in patients with epilepsy. Four out of 30 patients have already been enrolled and the results will be available at the end of quarter three next year.
JP Errico CEO of electroCore commented “We are delighted with the progress we are making. The open label trials we have run were very encouraging and we are confident that next year these randomized controlled trials will confirm that our non invasive vagus nerve stimulation VNS offers a significant benefit to patients with many types of serious headaches."
Contacts
MEDIA:
Simon VanePercy
+44(0)1737821890
simon@vanepercy.com
Permalink: http://me-newswire.net/news/9040/en
(BUSINESS WIRE)-- Following the announcement last month that it had fully enrolled its pilot FDA chronic migraine study electroCore has announced that its European randomized controlled trial, GC - 002, for the prevention and acute treatment of chronic cluster headache has been found by the external statistical team to require no changes based on the planned interim sizing analysis.
This study, which is a multicentre trial with sites in Germany -5, UK -3, Belgium -1, Italy -1, has as its primary outcome the reduction in the number of cluster headache attacks per week. The trial is a randomized controlled study involving parallel groups. One arm receiving the standard of care while the other arm is receiving the standard of care plus treatment with gammaCore - electroCore's non invasive vagus nerve stimulation (nVNS) therapy. The trial, which is due to finish at the end of the second quarter next year, has already enrolled 58 patients with a target total of 90 patients.
electroCore's extensive clinical trials program is continuing to explore the potential of its revolutionary non invasive vagus nerve stimulation therapy across a number of conditions. Surgically invasive vagus nerve stimulation therapy has proven to be very effective in epilepsy and depression but because of its very high cost is not used except as a last resort. Its high cost has also deterred research into the many conditions where it is reported to have been effective.
Several other key electroCore headache trials are also underway.
A European acute treatment of cluster headache trial has just started recruitment.
This randomized controlled study has two parallel groups one using gammaCore, the other a sham device. The trial is being run across eight sites - UK - 4, Germany 2, Denmark -1 and Netherlands 1. The results are expected in the third quarter of next year.
A pivotal FDA trial into the acute relief of cluster headaches is being carried out across nineteen sites in the US with 78 patients already enrolled. The final number of patients required, between 150 and 300, will be determined by an interim analysis by an outside statistical team based on the first 75 completed patients by the end of the year. This trial is measuring the level of pain on a five point scale 15 minutes after patients have self treated an acute cluster headache attack with the gammaCore device. The results are expected at the end of next year.
An epilepsy trial using electroCore’s nVNS therapy, the first clinical study of nVNS in this indication, is now being run at two sites in Australia. The randomized controlled, parallel-group, crossover trial using a sham device will measure the reduction of seizures in patients with epilepsy. Four out of 30 patients have already been enrolled and the results will be available at the end of quarter three next year.
JP Errico CEO of electroCore commented “We are delighted with the progress we are making. The open label trials we have run were very encouraging and we are confident that next year these randomized controlled trials will confirm that our non invasive vagus nerve stimulation VNS offers a significant benefit to patients with many types of serious headaches."
Contacts
MEDIA:
Simon VanePercy
+44(0)1737821890
simon@vanepercy.com
Permalink: http://me-newswire.net/news/9040/en
Hilton Worldwide Completes Over 2,400 Volunteer Projects During Annual Global Week of Service
MCLEAN, Va. - Wednesday, October 30th 2013 [ME NewsWire]
(BUSINESS WIRE) Hilton Worldwide celebrated the company’s annual volunteer campaign completing more than 2,400 volunteer projects in over 700 cities in 72 countries throughout the month of October. Now in its second year, Global Week of Service is Hilton Worldwide’s largest annual volunteer service event which recognizes the company’s service and volunteer culture and strengthens the communities Hilton Worldwide serves.
Team Members from over 900 properties and offices completed projects including résumé building for and mentoring of youth, refurbishment of schools and community centers, preservation of cultural landmarks, river and park clean-ups, meal preparation and the creation of community gardens and green spaces. All of the projects focused on engaging Team Members to deliver Hilton Worldwide's commitment to Travel with PurposeTM and its corporate responsibility pillars: creating opportunities, strengthening communities, celebrating cultures and living sustainably. Throughout the past year, Team Members have donated over 150,000 volunteer hours globally.
“Our second annual Global Week of Service exceeded our goals, allowing us to make an even greater impact on the communities where we live, work and travel,” said Christopher J. Nassetta, president and chief executive officer, Hilton Worldwide. “Exceptional service is at the core of what we deliver every day for millions of guests around the world, and Hilton Worldwide’s Global Week of Service is another opportunity for us to bring our Team Members together and celebrate our passion to serve.”
To help facilitate Global Week of Service and other volunteer projects across its global footprint, Hilton Worldwide leverages the Purpose Portal, a customized volunteer tool that connects Team Members with projects and organizations in their communities and recruits volunteers for thousands of organizations around the world. The platform also provides resources for the company’s global network of thousands of community and sustainability champions and volunteer project organizers enabling Hilton Worldwide to empower Team Members to take a leadership role in planning activities not only for its Global Week of Service, but also year-round.
Throughout Global Week of Service, Hilton Worldwide’s network of partners, including Points of Light, Hilton in the Community Foundation, Global Soap Project and Feeding America in addition to more than 1,300 local community organizations supported the company’s Team Members as they participated in community service projects around the globe.
Examples of volunteer projects during this year’s Global Week of Service include:
Americas
Across the United States and Canada, teams worked to improve conditions in the communities the company serves. In Memphis, TN, Team Members volunteered more than 430 hours to create new living spaces at Door of Hope. In McLean, VA over 6,000 pounds of food were assembled into weekend packs for students and emergency kits for food bank clients. Team Members in Orlando, FL made improvements to the Coalition for the Homeless facility and supported the launch of a new family program for their communities. And in Los Angeles, more than 80 volunteers from area hotels came together to create a sustainable, edible garden and irrigation system for more than 1,700 middle school students. Members of the Hilton Worldwide community also revitalized outdoor schools, food pantries and community shelters; hosted cultural events and learning sessions; and mentored youth about the skills needed in the hospitality sector.
In Colombia, Hilton Bogota and Hilton Cartagena Team Members volunteered more than 144 hours to join with a local school to refurbish its facilities and outdoor learning environment to create a safe space for children to learn.
Europe, Middle East & Africa
Team Members participated in more than 250 projects including preserving the banks of the Thames River in London where 48 bags of rubbish were removed and saplings were planted along the river; cleaning the Burgazada Coast in Istanbul, Turkey where 253.5 kg of garbage was removed; serving 280 youth in Frankfurt, Germany by installing a library to serve multicultural students at the Gunderrode Primary School; refurbishing and renovating the Al Garhoud National Charity School in Dubai, United Arab Emirates and revitalizing the Breakspeare School in Watford, UK which serves children with special needs.
Asia Pacific
Hundreds of volunteers joined together to create significant impact in their communities. In Thailand, 700 volunteers from Hilton Worldwide’s portfolio of properties throughout the country served with 10 community partners in Bangkok, Pattaya, Hua Hin, Phuket and Koh Samui. Mt. Fuji was the project site for Hilton Worldwide’s Japan corporate and hotel Team Members who dedicated multiple days to clean-up efforts at the national landmark. Team Members in Singapore spent two full days improving the lives of nearly 400 youth and senior citizens by providing meals, care packages and hospitality to Sunbeam Place and Peace Connect.
During the Week, Team Members were encouraged to share their personal stories of service and hospitality through a variety of channels. Photos and stories from the events are now posted at www.hiltonworldwide.com/serve, on the Hilton Worldwide Facebook page, on Flickr and on the @HiltonWorldwide Twitter account.
About Hilton Worldwide
Hilton Worldwide is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 94 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company’s portfolio of ten world-class global brands is comprised of more than 4,000 managed, franchised, owned and leased hotels and timeshare properties, with more than 665,000 rooms in 90 countries and territories, including Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonorsTM. Visit www.hiltonworldwide.com for more information and connect with Hilton Worldwide at www.facebook.com/hiltonworldwide, www.twitter.com/hiltonworldwide, www.youtube.com/hiltonworldwide, www.flickr.com/hiltonworldwide and www.linkedin.com/company/hilton-worldwide.
About Travel with PurposeTM
Travel with PurposeTM is Hilton Worldwide's corporate responsibility commitment to providing shared value to its business and communities in four areas - creating opportunities for individuals to reach their full potential; strengthening communities where Hilton Worldwide operates; celebrating cultures and the power of travel; and living sustainably through the measurement, analysis and improvement of the company's use of natural resources.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131030005205/en/
Contacts
Hilton Worldwide
Sarah Lipman
(703) 883-5315
sarah.lipman@hilton.com
Permalink: http://www.me-newswire.net/news/9017/en
(BUSINESS WIRE) Hilton Worldwide celebrated the company’s annual volunteer campaign completing more than 2,400 volunteer projects in over 700 cities in 72 countries throughout the month of October. Now in its second year, Global Week of Service is Hilton Worldwide’s largest annual volunteer service event which recognizes the company’s service and volunteer culture and strengthens the communities Hilton Worldwide serves.
Team Members from over 900 properties and offices completed projects including résumé building for and mentoring of youth, refurbishment of schools and community centers, preservation of cultural landmarks, river and park clean-ups, meal preparation and the creation of community gardens and green spaces. All of the projects focused on engaging Team Members to deliver Hilton Worldwide's commitment to Travel with PurposeTM and its corporate responsibility pillars: creating opportunities, strengthening communities, celebrating cultures and living sustainably. Throughout the past year, Team Members have donated over 150,000 volunteer hours globally.
“Our second annual Global Week of Service exceeded our goals, allowing us to make an even greater impact on the communities where we live, work and travel,” said Christopher J. Nassetta, president and chief executive officer, Hilton Worldwide. “Exceptional service is at the core of what we deliver every day for millions of guests around the world, and Hilton Worldwide’s Global Week of Service is another opportunity for us to bring our Team Members together and celebrate our passion to serve.”
To help facilitate Global Week of Service and other volunteer projects across its global footprint, Hilton Worldwide leverages the Purpose Portal, a customized volunteer tool that connects Team Members with projects and organizations in their communities and recruits volunteers for thousands of organizations around the world. The platform also provides resources for the company’s global network of thousands of community and sustainability champions and volunteer project organizers enabling Hilton Worldwide to empower Team Members to take a leadership role in planning activities not only for its Global Week of Service, but also year-round.
Throughout Global Week of Service, Hilton Worldwide’s network of partners, including Points of Light, Hilton in the Community Foundation, Global Soap Project and Feeding America in addition to more than 1,300 local community organizations supported the company’s Team Members as they participated in community service projects around the globe.
Examples of volunteer projects during this year’s Global Week of Service include:
Americas
Across the United States and Canada, teams worked to improve conditions in the communities the company serves. In Memphis, TN, Team Members volunteered more than 430 hours to create new living spaces at Door of Hope. In McLean, VA over 6,000 pounds of food were assembled into weekend packs for students and emergency kits for food bank clients. Team Members in Orlando, FL made improvements to the Coalition for the Homeless facility and supported the launch of a new family program for their communities. And in Los Angeles, more than 80 volunteers from area hotels came together to create a sustainable, edible garden and irrigation system for more than 1,700 middle school students. Members of the Hilton Worldwide community also revitalized outdoor schools, food pantries and community shelters; hosted cultural events and learning sessions; and mentored youth about the skills needed in the hospitality sector.
In Colombia, Hilton Bogota and Hilton Cartagena Team Members volunteered more than 144 hours to join with a local school to refurbish its facilities and outdoor learning environment to create a safe space for children to learn.
Europe, Middle East & Africa
Team Members participated in more than 250 projects including preserving the banks of the Thames River in London where 48 bags of rubbish were removed and saplings were planted along the river; cleaning the Burgazada Coast in Istanbul, Turkey where 253.5 kg of garbage was removed; serving 280 youth in Frankfurt, Germany by installing a library to serve multicultural students at the Gunderrode Primary School; refurbishing and renovating the Al Garhoud National Charity School in Dubai, United Arab Emirates and revitalizing the Breakspeare School in Watford, UK which serves children with special needs.
Asia Pacific
Hundreds of volunteers joined together to create significant impact in their communities. In Thailand, 700 volunteers from Hilton Worldwide’s portfolio of properties throughout the country served with 10 community partners in Bangkok, Pattaya, Hua Hin, Phuket and Koh Samui. Mt. Fuji was the project site for Hilton Worldwide’s Japan corporate and hotel Team Members who dedicated multiple days to clean-up efforts at the national landmark. Team Members in Singapore spent two full days improving the lives of nearly 400 youth and senior citizens by providing meals, care packages and hospitality to Sunbeam Place and Peace Connect.
During the Week, Team Members were encouraged to share their personal stories of service and hospitality through a variety of channels. Photos and stories from the events are now posted at www.hiltonworldwide.com/serve, on the Hilton Worldwide Facebook page, on Flickr and on the @HiltonWorldwide Twitter account.
About Hilton Worldwide
Hilton Worldwide is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 94 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company’s portfolio of ten world-class global brands is comprised of more than 4,000 managed, franchised, owned and leased hotels and timeshare properties, with more than 665,000 rooms in 90 countries and territories, including Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonorsTM. Visit www.hiltonworldwide.com for more information and connect with Hilton Worldwide at www.facebook.com/hiltonworldwide, www.twitter.com/hiltonworldwide, www.youtube.com/hiltonworldwide, www.flickr.com/hiltonworldwide and www.linkedin.com/company/hilton-worldwide.
About Travel with PurposeTM
Travel with PurposeTM is Hilton Worldwide's corporate responsibility commitment to providing shared value to its business and communities in four areas - creating opportunities for individuals to reach their full potential; strengthening communities where Hilton Worldwide operates; celebrating cultures and the power of travel; and living sustainably through the measurement, analysis and improvement of the company's use of natural resources.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131030005205/en/
Contacts
Hilton Worldwide
Sarah Lipman
(703) 883-5315
sarah.lipman@hilton.com
Permalink: http://www.me-newswire.net/news/9017/en
NYSE Euronext Update on Acquisition by IntercontinentalExchange
ME Newswire / Businesswire
NEW YORK - Thursday, October 31st 2013
NYSE Euronext (NYSE: NYX) today provided the following statement and timeline for the completion of its pending acquisition by IntercontinentalExchange (NYSE: ICE), a leading operator of global markets and clearing houses.
ICE and NYSE Euronext have postponed the closing date of their previously announced merger transaction from November 4, 2013 to a later date to be announced to allow additional time for relevant European regulators and ministries to process and issue their approvals. As previously announced, ICE and NYSE Euronext have received a letter from the Chairmen’s Committee of the Euronext College of Regulators, which includes each individual regulator of the Euronext markets, indicating that it is “not minded to object” to ICE’s proposed acquisition. ICE and NYSE Euronext are awaiting receipt of the remaining national regulatory approvals, which they expect to receive in the coming days, and anticipate closing the proposed transaction within two business days after receipt of the final regulatory approval. Neither ICE nor NYSE Euronext anticipates any substantive issues being raised in the context of these remaining European national approvals.
ICE and NYSE Euronext have not extended the election deadline for shareholders of NYSE Euronext to make merger consideration elections of stock and/or cash consideration, which remains 5:00 p.m., New York City time, on October 31, 2013, with such election deadline being fixed unless extended by ICE through further public announcement. Shareholders of NYSE Euronext who hold shares through a financial intermediary such as a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee in order to comply with any earlier deadline. Shareholders of NYSE Euronext with questions regarding the election procedures or materials should contact their financial intermediary, or Georgeson Inc., the information agent for the transaction, at 888-566-8006 (toll free in the United States) or 781-575-2137 (outside the United States).
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. For more information, please visit: http://www.nyx.com.
Please follow us at:
Exchanges Blog Facebook LinkedIn Twitter
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This written communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other “forward-looking” information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.
Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE’s and NYSE Euronext’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE’s and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext’s operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE’s, NYSE Euronext’s or the combined company’s respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled “Risk Factors” in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S-4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus has been delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT CONTAINS IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC’s website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE’s website at http://www.theice.com and from NYSE Euronext’s website at http://www.nyx.com.
Contacts
NYSE Euronext
Media
Robert Rendine, 212-656-2180
rrendine@nyx.com
Eric Ryan, 212-656-2411
eryan@nyx.com
Caroline Tourrier, +33 (0)1 49 27 10 82
ctourrier@nyx.com
Investor Relations
Stephen Davidson, 212-656-2183
sdavidson@nyx.com
Permalink: http://me-newswire.net/news/9031/en
NEW YORK - Thursday, October 31st 2013
NYSE Euronext (NYSE: NYX) today provided the following statement and timeline for the completion of its pending acquisition by IntercontinentalExchange (NYSE: ICE), a leading operator of global markets and clearing houses.
ICE and NYSE Euronext have postponed the closing date of their previously announced merger transaction from November 4, 2013 to a later date to be announced to allow additional time for relevant European regulators and ministries to process and issue their approvals. As previously announced, ICE and NYSE Euronext have received a letter from the Chairmen’s Committee of the Euronext College of Regulators, which includes each individual regulator of the Euronext markets, indicating that it is “not minded to object” to ICE’s proposed acquisition. ICE and NYSE Euronext are awaiting receipt of the remaining national regulatory approvals, which they expect to receive in the coming days, and anticipate closing the proposed transaction within two business days after receipt of the final regulatory approval. Neither ICE nor NYSE Euronext anticipates any substantive issues being raised in the context of these remaining European national approvals.
ICE and NYSE Euronext have not extended the election deadline for shareholders of NYSE Euronext to make merger consideration elections of stock and/or cash consideration, which remains 5:00 p.m., New York City time, on October 31, 2013, with such election deadline being fixed unless extended by ICE through further public announcement. Shareholders of NYSE Euronext who hold shares through a financial intermediary such as a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee in order to comply with any earlier deadline. Shareholders of NYSE Euronext with questions regarding the election procedures or materials should contact their financial intermediary, or Georgeson Inc., the information agent for the transaction, at 888-566-8006 (toll free in the United States) or 781-575-2137 (outside the United States).
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. For more information, please visit: http://www.nyx.com.
Please follow us at:
Exchanges Blog Facebook LinkedIn Twitter
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This written communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other “forward-looking” information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.
Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE’s and NYSE Euronext’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE’s and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext’s operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE’s, NYSE Euronext’s or the combined company’s respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled “Risk Factors” in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S-4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus has been delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT CONTAINS IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC’s website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE’s website at http://www.theice.com and from NYSE Euronext’s website at http://www.nyx.com.
Contacts
NYSE Euronext
Media
Robert Rendine, 212-656-2180
rrendine@nyx.com
Eric Ryan, 212-656-2411
eryan@nyx.com
Caroline Tourrier, +33 (0)1 49 27 10 82
ctourrier@nyx.com
Investor Relations
Stephen Davidson, 212-656-2183
sdavidson@nyx.com
Permalink: http://me-newswire.net/news/9031/en
Subscribe to:
Posts (Atom)